EDAP to Accelerate Treatment Rates at Study Centers

EDAP TMS S.A. to Release 2007 First Quarter Results LYON, France , May 7 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and distribution

Duke Performs First Treatments under EDAP Study Sponsorship

From UroToday.com: Ablatherm® - HIFU: A New Perspective in 2007, the Year of the First Long Term Clinical Results on the Treatment of Localised Prostate Cancer UroToday.com announced today the addition of Ablatherm® - HIFU: A New Perspective in 2007, the Year of the First Long Term Clinical Results

EDAP Announces Details on Termination Agreement With HealthTronics LYON, France, April 12 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production,

Company Reclaims Full US Market Rights; Ablatherm-HIFU Trial to Resume Immediately

Company Restarts US Trials for Localized Prostate Cancer HIFU

Longest HIFU Clinical Results Confirm Addition to Standard of Care Protocols; Symposium Confirms Ablatherm Strong Outcomes

Six-City Tour Generates Awareness, Training Demand for Ablatherm-HIFU TherapyEAU Congress Interest Advances German Market Growth

Distributor Meeting, User Group Sessions, Media Conferences to Highlight Ablatherm-HIFU